Open AccessSevere eosinophilic bronchial asthma: new therapeutic options
Author(s) -
Н.М. Ненашева
Publication year - 2018
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2018-15-44-52
Subject(s) - mepolizumab , asthma , medicine , eosinophilic , monoclonal antibody , immunology , eosinophil , phenotype , eosinophilia , pathogenesis , pathology , antibody , biology , gene , biochemistry
Eosinophilic asthma is a common phenotype of severe asthma, occurring in at least half of patients. In recent years, there have been significant changes in the approaches to the treatment of severe bronchial asthma and, above all, eosinophilic asthma. The article discusses the role of eosinophils in the pathogenesis of severe asthma, the detection of the phenotype of severe eosinophilic asthma, and modern approaches to targeting severe asthma with an eosinophilic phenotype using biological agents. A special emphasis is placed on preparations of monoclonal antibodies to interleukin-5, in particular, mepolizumab, recently approved for clinical use in our country.